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Abstract
Objective To study the risk of adverse pregnancy outcomes in women
with polycystic ovary syndrome, taking into account maternal
characteristics and assisted reproductive technology.
Design Population based cohort study.
Setting Singleton births registered in the Swedish medical birth register
between 1995 and 2007.
Participants By linkage with the Swedish patient register, 3787 births
among women with a diagnosis of polycystic ovary syndrome and 1 191
336 births among women without such a diagnosis.
Main outcome measures Risk of adverse pregnancy outcomes
(gestational diabetes, pre-eclampsia, preterm birth, stillbirth, neonatal
death, low Apgar score (<7 at five minutes), meconium aspiration, large
for gestational age, macrosomia, small for gestational age), adjusted for
maternal characteristics (body mass index, age), socioeconomic factors
(educational level, and cohabitating with infant’s father), and assisted
reproductive technology.
Results Women with polycystic ovary syndrome were more often obese
and more commonly used assisted reproductive technology than women
without such a diagnosis (60.6% v 34.8% and 13.7% v 1.5%). Polycystic
ovary syndrome was strongly associated with pre-eclampsia (adjusted
odds ratio 1.45, 95% confidence interval 1.24 to 1.69) and very preterm
birth (2.21, 1.69 to 2.90) and the risk of gestational diabetes was more
than doubled (2.32, 1.88 to 2.88). Infants born to mothers with polycystic
ovary syndrome were more prone to be large for gestational age (1.39,
1.19 to 1.62) and were at increased risk of meconium aspiration (2.02,
1.13 to 3.61) and having a low Apgar score (<7) at five minutes (1.41,
1.09 to 1.83).
Conclusions Women with polycystic ovary syndrome are at increased
risk of adverse pregnancy and birth outcomes that cannot be explained
by assisted reproductive technology. These women may need increased
surveillance during pregnancy and parturition.
Introduction
Polycystic ovary syndrome is one of the most common
endocrine disorders, affecting about 5-15% of women of
reproductive age.
1-3 The condition is characterised by
oligo-ovulation or anovulation, biochemical or clinical
hyperandrogenism, and polycystic ovaries. According to the
Rotterdam consensus from 2003, the presence of two of three
of these criteria fulfils a diagnosis of polycystic ovary
syndrome.
4Thecauseofpolycysticovarysyndromeisnotfully
understood, but evidence of a genetic component has been
recognised in family and twin studies.
5 Oligo-ovulation or
anovulation in women with polycystic ovary syndrome is a
major cause of infertility, and such women might require
ovulation induction or assisted reproductive technology to
become pregnant.
6 Changes to lifestyle can, however, improve
themetabolicandendocrineconsequencesofhavingpolycystic
ovary syndrome, thus possibly improving infertility caused by
anovulation.
7
Evidencesuggeststhatpolycysticovarysyndromehasanegative
impact on pregnancy outcomes, with an increased risk of
gestational diabetes, hypertensive disease during pregnancy,
and preterm birth.
8 Available studies are, however, limited in
size and have mainly included women undergoing assisted
reproductive technology.
8 9 Consequently the extent to which
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Research
RESEARCHthe risk of adverse pregnancy outcomes in women with
polycystic ovary syndrome is attributed to the underlying
disorder or infertility treatment is uncertain. We carried out a
large nationwide cohort study of pregnant women, including
pregnancies conceived spontaneously and by assisted
reproductive technology to evaluate the risks of adverse
pregnancy and birth outcomes in women with polycystic ovary
syndrome.
Methods
From the Swedish medical birth register we created a cohort
amongwomenwithsingletonpregnanciesgivingbirthbetween
1995 and 2007. Women with polycystic ovary syndrome are
more likely to undergo assisted reproductive technology, with
itshigherfrequencyoftwinsandhighermultiplebirths.Because
twinandmultiplepregnanciesdifferinfetalgrowthandduration
of gestation and have a higher occurrence of complications
duringpregnancyweexcludedsuchpregnanciesfromthestudy
population.
Using the unique personal identification number assigned to
each citizen at birth or immigration we linked data from the
Swedish medical birth register with the Swedish patient and
education registers.
10 The Swedish patient register, established
in 1964 (nationwide since 1987), includes information on dates
of hospital admissions, discharges, and diagnoses classified
accordingtoICDcodes(internationalclassificationofdiseases,
7-10th revisions). Since 2001 this registry has also included
informationonout-patienthospitalvisits.Werecordedthedate
of the first diagnosis of polycystic ovary syndrome according
to ICD codes: ICD-7, 275.20 and ICD-8, 256.90
(Stein-Leventhalssyndrome);ICD-9,256E;andICD-10,E28.2.
In the Swedish version of ICD-7 and ICD-8 the codes
correspond to the formerly known Stein-Leventhals syndrome.
ForICD-9andICD-10thecodeisspecifiedaspolycysticovary
syndrome and Stein-Leventhals syndrome.
Register data
DatafromtheSwedishmedicalbirthregisterincludeinformation
on about 98% of births in Sweden, with information on the
mother as well as the pregnancy, delivery, and neonatal period.
Data are prospectively collected, starting at the woman’s first
antenatal visit.
11
We classified maternal age (years) at birth into four groups:
13-24, 25-29, 30-34, and ≥35. Body mass index was calculated
(weight (kg)/(height (m)
2) and the women categorised as lean
(bodymassindex≤19.9),normalweight(20.0-24.9),overweight
(25.0-29.9), or obese (≥30.0). Parity was classified into
nulliparous or parous women. Through linkage with the
education register we obtained information on the number of
years of formal education completed as of 1 January 2008,
categorised as 11 or fewer or 12 or more. Cigarette smoking
was recorded as none, 1-9 cigarettes daily, or 10 or more
cigarettesdaily.TheSwedishmedicalbirthregisteralsocontains
informationonwhetherthepregnancywasconceivedbyassisted
reproductive technology or not and information on concurrent
diseases such as diabetes mellitus and essential hypertension
bycheckboxaswellasICD-9andICD-10codes.Pre-eclampsia
was defined as a blood pressure reading of 140/90 mm Hg or
more with proteinuria of more than 0.3 g over 24 hours.
Gestationaldiabeteswas,accordingtoclinicalpractice,defined
as plasma glucose levels of 12.2 mmol/L or more after oral
glucose tolerance test (75 g glucose orally administered and
plasma glucose measured after two hours) or fasting blood
glucose levels of 7.0 mmol/L or more. Infants born small for
gestationalageweredefinedashavingbirthweightsoflessthan
2 standard deviations below the mean for gestational age and
sexoftheinfant.Similarly,largeforgestationalagewasdefined
as a birth weight of more than 2 standard deviations above the
mean for gestational age. Macrosomia was defined as a birth
weight of 4500 g or more. Post-term pregnancy was defined as
delivery at 42 weeks or more of gestation and preterm birth as
delivery at less than 37 weeks of gestation, classified as
moderately (32+0 to 36+6 weeks) and very preterm birth (<32
weeks). Stillbirth was defined as intrauterine fetal death after
28 weeks of gestation. A low Apgar score was defined as less
than 7 at five minutes. Neonatal death was defined as death of
the infant from 0 to 27 days after birth. The presence of
meconium aspiration was obtained by diagnosis at discharge.
Statistical analysis
The main outcome measures were gestational diabetes,
pre-eclampsia, preterm birth, stillbirth, neonatal death, low
Apgar score, meconium aspiration, large for gestational age,
macrosomia, and small for gestational age. Using logistic
regressionweestimatedtheriskofadversepregnancyoutcomes
in relation to polycystic ovary syndrome by crude and adjusted
odds ratios with 95% confidence intervals. Data were analysed
usingtheSASsoftwareversion9.2.Wecomparedwomenwith
a diagnosis of polycystic ovary syndrome with women with no
such diagnosis, taking into account possible confounders, such
as maternal age, body mass index, parity, years of formal
education, cigarette consumption, undergoing assisted
reproductivetechnology,andcalendaryearofdelivery.Absolute
rateswerestandardisedfordifferenceincharacteristicsbetween
women with and without polycystic ovary syndrome. In
additional analyses we tested for residual confounding for the
variables maternal age, body mass index, and parity by a finer
categorisation and by analysing the continuous variables in a
linear or linear-quadratic model.
Assisted reproductive technology refers only to in vitro
fertilisation including intracytoplasmic sperm injection and not
other forms of assisted reproductive technology such as
ovulation induction or insemination.
Womentendtorepeatpregnancyoutcomesinsuccessivebirths.
Among women with polycystic ovary syndrome, 74.1%
deliveredoneinfantduringthestudyperiod,23.2%twoinfants,
and 2.7% three or more infants. The corresponding frequencies
amongwomenwithoutpolycysticovarysyndromewere53.0%,
38.1%, and 8.9%. Because observations are not independent in
women who delivered more than once during the study period,
we calculated estimates using clustered data in the generalised
estimation equation method (PROC GENMOD). We used a
formal interaction test in the logistic regression model to
estimatethepossibleeffectmodificationofassistedreproductive
technology and body mass index on the association between
polycystic ovary syndrome and preterm birth.
Results
A total of 1 195 123 singleton births between 1995 and 2007
were included in the cohort, with 3787 births among mothers
with a diagnosis of polycystic ovary syndrome. Women with
polycystic ovary syndrome were more likely to be nulliparous
than women with no such diagnosis (53.0%, n=1990 v 43.8%,
n=520 106, P<0.001). Undergoing assisted reproductive
technologywasmorecommoninwomenwithpolycysticovary
syndrome(13.7%,n=510v1.5%,n=18058,P<0.001).Women
with polycystic ovary syndrome had an almost doubled
prevalence of a body mass index greater than 25.0 (60.6%,
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RESEARCHn=1980 and 34.8%, n=348 340, P<0.001). Giving birth at
advancedmaternalage(>35years)wasmorecommoninwomen
with than without polycystic ovary syndrome (19.9%, n=753
and17.6%,n=209125,P<0.001).Womenwithpolycysticovary
syndrome were more likely to have hypertensive disease and
diabetes mellitus than women without polycystic ovary
syndrome (table 1⇓).
Tables2⇓and3⇓presentabsoluterates,absoluteriskdifferences
standardisedforthedifferenceincharacteristicsbetweenwomen
with and without polycystic ovary syndrome, and crude and
adjustedrelativerisksforadversepregnancyandbirthoutcomes.
In the adjusted analysis, women with a previous diagnosis of
polycystic ovary syndrome had a higher risk of developing
gestational diabetes than women with no such diagnosis
(adjustedoddsratio2.32,95%confidenceinterval1.88to2.88),
whereastheadjustedriskdifferencewas1.81%.Therewasalso
a strong association between polycystic ovary syndrome and
pre-eclampsia (1.45, 1.24 to 1.69) and very preterm birth (2.21,
1.69 to 2.90). Women with polycystic ovary syndrome had an
18% higher risk of undergoing caesarean section (both
emergency and elective) compared with women without
polycystic ovary syndrome (table 2).
Infants born to mothers with a previous diagnosis of polycystic
ovarysyndromeweremoreoftenlargeforgestationalage(1.39,
1.19 to 1.62) and were also at increased risk of meconium
aspiration (2.02, 1.13 to 3.61) and a low Apgar score at five
minutes (1.41, 1.09 to 1.83). The risk of neonatal death was not
significantly increased (1.58, 0.81 to 3.07; table 3). No residual
confoundingformaternalage,bodymassindex,andparitywas
found in sensitivity analyses (data not shown).
In a stratified analysis the adjusted odds ratio for preterm birth
(<37+0weeks)amongwomenwithpolycysticovarysyndrome
undergoing assisted reproductive technology was 1.08 (95%
confidence interval 0.76 to 1.53) and among women with
polycysticovarysyndromeconceivingspontaneouslywas1.58
(1.33to1.79)(P=0.055forinteraction,table4⇓).Theinteraction
between body mass index and polycystic ovary syndrome and
the association with preterm birth was not significant.
Discussion
In the present population based study a diagnosis of polycystic
ovary syndrome was associated with increased risks of adverse
pregnancyoutcomesthatcouldnotbeattributedtotheincreased
use of assisted reproductive technology or maternal
characteristics such as advanced age or being overweight or
obese.
Comparison with other studies
Inpreviousstudiespretermbirthhasbeencorrelatedtoassisted
reproductive technology, obesity, and polycystic ovary
syndrome.
8 12 13 This is in congruence with the findings of this
study and furthermore we also found that the risk of preterm
birth among women with polycystic ovary syndrome could not
be explained by maternal characteristics such as advanced age,
smoking, obesity, or use of assisted reproductive technology.
There was an interaction between assisted reproductive
technology and polycystic ovary syndrome for preterm birth.
Since women with polycystic ovary syndrome often need
assisted reproductive technology or ovulation induction to
become pregnant, the risk of multiple births increases, which
isassociatedwithpretermbirth.Inpreviousreportsthestrongest
predictor for preterm birth in women with polycystic ovary
syndrome was multiple birth.
14 A meta-analysis
8 found a 75%
increased risk of preterm birth in women with polycystic ovary
syndrome, but when mean length of gestation was analysed
women with polycystic ovary syndrome and controls did not
differ.
We found a higher proportion of macrosomia and being large
for gestational age among infants of mothers with polycystic
ovarysyndrome.Thisfindingiscontroversialsincetheavailable
studies have not established this association.
14-16 It is well
foundedthatmaternalobesityisassociatedwithincreasedbirth
weight in offspring
17 18 as well as glucose intolerance and
gestational diabetes.
19 Women with polycystic ovary syndrome
are in general more overweight than women without the
condition. The estimates in the present study were, however,
adjusted for body mass index, suggesting that polycystic ovary
syndrome may increase the rate of fetal growth independently.
Womenwithpolycysticovarysyndromeare,regardlessofbody
mass index, at increased risk of developing gestational
diabetes,
8 20 supported by our finding. Infants born to mothers
with polycystic ovary syndrome were more likely to have low
Apgar scores at five minutes and to experience meconium
aspiration. These infants may be more susceptible to fetal
distress during labour. However, there was no association with
stillbirth, and the increased risk for neonatal death was not
statistically significant. These findings need to be confirmed in
future studies.
We observed a strong association between polycystic ovary
syndromeandpre-eclampsia.Somestudieshavesupportedthis
finding,
8 21 and others not.
14 It is well stated that women
undergoing assisted reproductive technology are at increased
risk of hypertensive disease during pregnancy,
22 23 which has
been attributed to the underlying cause of infertility. In one
study
24 the risk of being born small for gestational age in the
offspring of women with polycystic ovary syndrome was
increased, whereas this could not be confirmed in other
studies.
14-16 We could not find any such correlation, suggesting
that maternal polycystic ovary syndrome is not associated with
growth restriction.
The increased risk of caesarean section among women with
polycystic ovary syndrome we found does not correspond with
the findings of other studies. In a meta-analysis,
8 women with
polycystic ovary syndrome showed a significantly higher rate
of caesarean section (odds ratio 1.56, 95% confidence interval
1.20 to 2.02), but in a subgroup analysis restricted to studies of
higher validity no significant risk was observed (0.92, 0.54 to
1.58). Obesity has been shown to be an independent risk factor
for caesarean delivery.
25 In the present study, however, obesity
was accounted for in the adjusted analysis.
Women with polycystic ovary syndrome can conceive
spontaneously but with a delayed fertile window since there is
a tendency of regular menstrual cycles with advancing age.
26 In
the present study we found that women with polycystic ovary
syndrome were slightly older than women without polycystic
ovary syndrome. Advanced maternal age is strongly correlated
with many of the adverse pregnancy outcomes in this study
27;
however, although we adjusted for maternal age in the
multivariate analysis, a residual effect could still be possible.
Strengths and limitations of the study
Amajorstrengthofthisstudywasthelargesamplesize,making
it possible to study rare pregnancy outcomes such as stillbirth,
meconium aspiration, low Apgar scores at five minutes, and
neonatal death. In this population based study we included
womenwithpregnanciesthatwerespontaneouslyconceivedas
wellasconceivedbyassistedreproductivetechnology.Women
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RESEARCHwith polycystic ovary syndrome according to the Rotterdam
criteria,
4 and not seeking medical assistance for irregular
menstrual periods or infertility problems, might have been
incorrectly classified as not having the disease. Such
misclassification would lead to an underestimation of the
association between polycystic ovary syndrome and adverse
pregnancy outcomes. When the National Institutes of Health
and Rotterdam criteria for polycystic ovary syndrome were
compared, the prevalence was doubled.
28 29 This may imply an
underestimation of women with polycystic ovary syndrome at
the start of the study period, when the National Institutes of
Health criteria was used. However, we adjusted for calendar
period in the multivariate analyses. Furthermore, it is likely that
we included women with more severe disease as exposed, and
thefindingsmayconsequentlynotbegeneralisabletoallwomen
with polycystic ovary syndrome.
Possible pathophysiological mechanisms
The pathophysiological mechanisms behind the increased risk
of adverse pregnancy outcomes among women with polycystic
ovary syndrome are not fully known. In this study, polycystic
ovary syndrome was associated with being overweight and
obese, with an increased risk of macrosomia and large for
gestational age infants, even after adjustments for body mass
index. A higher prevalence of pre-eclampsia and gestational
diabetesmayaccountforincreasedfetalstressleadingtopreterm
birth, low Apgar scores at five minutes, and meconium
aspiration. Women with polycystic ovary syndrome have
increasedlevelsofandrogens,whichhavebeenassociatedwith
thedevelopmentofpre-eclampsia.
30Metformintreatmentduring
pregnancydoesnotseemtolowermaternalandrogenlevelsbut
has been shown to decrease severe pregnancy and post-partum
complications,whichmaybemediatedbyreduceduterineartery
impedance.
31 32Ourresultsdonotsupportthenotionthatassisted
reproductivetechnologymediatesadversepregnancyoutcomes
among women with polycystic ovary syndrome. This finding
issupportedbyaNorwegianstudy,whichreportedthatadverse
outcomes are attributable to the factors leading to infertility
rather than to factors related to reproductive technology.
33
Conclusions
In conclusion, women with polycystic ovary syndrome are at
increased risk of adverse pregnancy and perinatal outcomes,
which could not be explained by assisted reproductive
technology. These women may need increased surveillance
duringpregnancyandparturition.Futureresearchwouldbenefit
from focusing on glucose control, medical treatment, and
hormonalstatusamongwomenwithpolycysticovarysyndrome
during pregnancy.
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RESEARCHWhat is already known on this topic
Women with polycystic ovary syndrome undergoing assisted reproductive technology have increased risks of gestational diabetes,
pre-eclampsia, and preterm birth
What this study adds
Irrespective of the use of assisted reproduction, polycystic ovary syndrome is associated with preterm birth, gestational diabetes, and
pre-eclampsia
Infants born to mothers with polycystic ovary syndrome are more likely to have a low Apgar score at five minutes, have meconium
aspiration, and be large for gestational age
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Table 1| Characteristics of women with and without polycystic ovary syndrome (PCOS) giving birth to singleton pregnancies (1 195 123
total births) in Sweden, 1995 to 2007
P value*
No of births (rate %)
Maternal characteristics Women without PCOS (n=1 191 336) Women with PCOS (n=3787)
Age (years):
<0.001 188 795 (15.85) 339 (8.95) 13-24
390 088 (32.74) 1180 (31.16) 25-29†
403 303 (33.85) 1515 (40.01) 30-34
209 125 (17.55) 753 (19.88) ≥35
25 0 Data missing
Body mass index:
<0.001 99 360 (9.91) 148 (4.53) ≤19.9
554 456 (55.33) 1140 (34.88) 20.0-24.9†
245 606 (24.51) 932 (28.52) 25.0-29.9
102 734 (10.25) 1048 (32.07) ≥30.0
189 180 519 Data missing
Parity:
<0.001 520 106 (43.66) 1990 (52.55) 0
671 206 (56.34) 1797 (47.45) ≥1†
24 0 Data missing
Education level (years):
0.47 663 449 (56.11) 2139 (56.69) ≤11
518 974 (43.89) 1634 (43.31) ≥12†
8913 14 Data missing
Cigarette consumption (daily):
0.003 988 375 (88.60) 3192 (90.42) None†
87 909 (7.88) 232 (6.57) 1-9
39 291 (3.52) 106 (3.00) ≥10
75 761 257 Data missing
Assisted reproductive technology:
<0.001 18 020 (1.51) 515 (13.60) Yes
1 173 316 (98.49) 3272 (86.40) No
Essential hypertension:
<0.001 3345 (0.28) 26 (0.69) Yes
1 187 991 (99.72) 3761 (99.31) No
Diabetes mellitus:
<0.001 4596 (0.38) 76 (2.01) Yes
1 186 767 (99.62) 3711 (97.99) No
*Wald test of overall effect (test of general heterogeneity).
†Reference group.
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RESEARCHTable 2| Pregnancy outcomes in women with and without polycystic ovary syndrome (PCOS) giving birth to singleton pregnancies (1 195
123 total births) in Sweden, 1995 to 2007
P value Adjusted odds
ratio† (95% CI)
Crude odds ratio†
(95% CI)
Standardised
absolute risk
No of births (rate %) Pregnancy outcomes
Women without PCOS
(n=1 191 336)
Women with PCOS
(n=3787)
difference* (%)
in women with
PCOS
Gestational diabetes:
<0.001 2.32 (1.88 to 2.88) 3.78 (3.16 to 4.52) 1.85 10 672 (0.90) 125 (3.30) Yes
1.00 1.00 — 1 180 664 (99.10) 3662 (96.70) No
Pre-eclampsia:
<0.001 1.45 (1.24 to1.69) 2.04 (1.78 to 2.34) 1.74 35 129 (2.95) 221 (5.84) Yes
1.00 1.00 — 1 156 207 (97.05) 3566 (94.16) No
Antepartum bleeding or
placental complications:
0.37 1.14 (0.85 to 1.53) 1.29 (0.99 to 1.66) — 14 490 (1.22) 59 (1.56) Yes
1.00 1.00 — 1 176 846 (98.78) 3728 (98.44) No
Caesarean section‡:
0.001 1.18 (1.07 to 1.29) 1.69 (1.56 to 1.82) 2.75 174 298 (14.68) 846 (22.44) Yes
1.00 1.00 — 1 013 112 (85.32) 2924 (77.56) No
— — — 30 0 Data missing
Very preterm birth (<31+6
weeks)‡:
<0.001 2.21 (1.69 to 2.90) 2.59 (2.02 to 3.31) 0.94 7999 (0.67) 65 (1.73) Yes
1.00 1.00 — 1 178 296 (99.33) 3701 (98.27) No
— — — 1145 4 Data missing
Moderately preterm birth
(32+0 to 36+6 weeks)‡§:
0.0004 1.31 (1.13 to 1.53) 1.46 (1.28 to 1.67) 1.38 50 352 (4.27) 226 (6.11) Yes
1.00 1.00 — 1 127 944 (95.73) 3475 (93.89) No
— — — 1145 4 Data missing
Post-term birth (>42+0
weeks)‡:
0.0069 0.82 (0.71 to 0.95) 0.91 (0.80 to 1.03) −1.39 86 771 (7.31) 252 (6.69) Yes
1.00 1.00 — 1 099 524 (92.69) 3514 (93.31) No
— — — 1145 4 Data missing
*Estimated for significantly associated outcomes.
†Adjusted for maternal age, parity, body mass index, years of education, cigarette consumption, assisted reproductive technology, and year of delivery.
‡Live births only.
§Risk compared with deliveries at 37 weeks and later.
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RESEARCHTable 3| Perinatal outcomes in women with and without polycystic ovary syndrome (PCOS) giving birth to singleton pregnancies (1 195
123 total births) in Sweden, 1995 to 2007
P value
Adjusted odds ratio*
(95% CI)
Crude odds ratio*
(95% CI)
Standardised
absolute risk
No of births (rate %)
Perinatal outcomes
WomenwithoutPCOS(n=1
191 336)
Women with PCOS
(n=3787)
difference (%)
in women with
PCOS†
Stillbirth:
0.73 0.90 (0.50 to 1.63) 1.38 (0.85 to 2.22) — 3896 (0.33) 17 (0.45) Yes
1.00 1.00 — 1 187 440 (99.67) 3770 (99.55) No
Apgar score <7 at 5
minutes‡:
0.0095 1.41 (1.09 to 1.83) 1.74 (1.38 to 2.21) 0.54 12 909 (1.10) 71 (1.89) Yes
1.00 1.00 — 1 165 776 (98.90) 3680 (98.11) No
— — — 8755 19 Data missing
Neonatal death (0-27
days)‡:
0.18 1.58 (0.81 to 3.07) 1.59 (0.88-´to 2.88) — 2179 (0.18) 11 (0.29) Yes
1.00 1.00 — 1 185 261 (99.82) 3759 (99.71) No
Meconium aspiration‡:
0.018 2.02 (1.13 to 3.61) 2.36 (1.37 to 4.07) 0.17 1738 (0.15) 13 (0.34) Yes
1.00 1.00 — 1 185 702 (99.85) 3757 (99.66) No
Large for gestational age:
<0.001 1.39 (1.19 to 1.62) 1.69 (1.48 to 1.93) 1.69 45 421 (3.84) 238 (6.32) Yes
1.00 1.00 — 1 138 532 (96.69) 3526 (93.68) No
— — — 7383 23 Data missing
Macrosomia (birth weight
≥4500 g):
0.072 1.16 (0.99 to 1.36) 1.29 (1.11 to 1.49) — 47 937 (4.04) 194 (5.14) Yes
1.00 1.00 — 1 139 030 (95.96) 3582 (94.86) No
— — — 4369 11 Data missing
Small for gestational age:
0.91 1.01 (0.81 to 1.27) 1.03 (0.84 to 1.27) — 27 192 (2.30) 89 (2.36) Yes
1.00 1.00 — 1 156 761 (97.70) 3675 (97.64) No
— — — 7383 23 Data missing
*Adjusted for maternal age, parity, body mass index, years of education, cigarette consumption, assisted reproductive technology, and year of delivery.
†Estimated for significantly associated outcomes.
‡Live births only.
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RESEARCHTable 4| Adjusted odds ratios of women with and without polycystic ovary syndrome (PCOS) and singleton preterm births (<37+0 weeks)
undergoing assisted reproductive technology in Sweden, 1995 to 2007
Adjusted odds
ratio† (95% CI) Rate
No assisted reproductive
technology*
Adjusted odds
ratio† (95% CI) Rate
Assisted reproductive technology*
Pretermbirth No Yes
Women without
PCOS WomenwithPCOS
1.54 (1.33 to
1.79)
7.83 58 723 256 1.08 (0.76 to
1.53)
7.96 1400 41 Yes
1.00 5.01 1 113 426 3012 1.00 7.77 16 618 474 No
— — 1167 4 — — — 2 Data missing
*P=0.055 for interaction analysis for assisted reproductive technology and PCOS in relation to preterm birth.
†Adjusted for maternal age, parity, body mass index, years of education, cigarette consumption, and assisted reproductive technology.
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RESEARCH